Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marla C Dubinsky

Showing results (21-30 of 286) with videos related to

Pageof 29
Sort By:
Current Gastroenterology Reports|May 26, 2009
Probiotics in pediatric inflammatory bowel diseasesAjay S Gulati, Marla C Dubinsky
Journal of Clinical Pharmacology|February 25, 2015
Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodiesDiane R Mould, Marla C Dubinsky
Inflammatory Bowel Diseases|September 11, 2015
The Evolving Role of Thiopurines for Inflammatory Bowel DiseaseDanya J Rosen, Marla C Dubinsky
Inflammatory Bowel Diseases|June 8, 2017
Fecal Calprotectin Levels Predict Histological Healing in Ulcerative ColitisAnish Patel, Hinaben Panchal, Marla C Dubinsky
Inflammatory Bowel Diseases|February 21, 2014
A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel diseaseElaheh Vahabnezhad, Shervin Rabizadeh, Marla C Dubinsky
Gastroenterology|April 18, 2022
Proactive Therapeutic Drug Monitoring of Adalimumab in Patients With Crohn's DiseaseKonstantinos Papamichael, Marla C Dubinsky, Adam S Cheifetz
Gastroenterology|April 17, 2021
Challenges and Opportunities in IBD Clinical Trial DesignMarla C Dubinsky, Rory Collins, Maria T Abreu, et al.
JAMA|September 21, 2021
Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory DiseasesKonstantinos Papamichael, Marla C Dubinsky, Adam S Cheifetz
Gastrointestinal Endoscopy Clinics of North America|September 17, 2016
The First Endoscopy in Suspected Inflammatory Bowel DiseaseRebecca A Fausel, Asher Kornbluth, Marla C Dubinsky
Journal of Crohn'S & Colitis|September 7, 2020
Therapeutic Drug Monitoring of Anti-tumour Necrosis Factor Agents in Inflammatory Bowel Diseases: The Jury Is Still OutManasi Agrawal, Marla C Dubinsky, Jean-Frederic Colombel
Pageof 29

Showing results (21-30 of 286) with videos related to

Sort By:
Pageof 29
Current Gastroenterology Reports|May 26, 2009
Probiotics in pediatric inflammatory bowel diseasesAjay S Gulati, Marla C Dubinsky
Journal of Clinical Pharmacology|February 25, 2015
Dashboard systems: Pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodiesDiane R Mould, Marla C Dubinsky
Inflammatory Bowel Diseases|September 11, 2015
The Evolving Role of Thiopurines for Inflammatory Bowel DiseaseDanya J Rosen, Marla C Dubinsky
Inflammatory Bowel Diseases|June 8, 2017
Fecal Calprotectin Levels Predict Histological Healing in Ulcerative ColitisAnish Patel, Hinaben Panchal, Marla C Dubinsky
Inflammatory Bowel Diseases|February 21, 2014
A 10-year, single tertiary care center experience on the durability of infliximab in pediatric inflammatory bowel diseaseElaheh Vahabnezhad, Shervin Rabizadeh, Marla C Dubinsky
Gastroenterology|April 18, 2022
Proactive Therapeutic Drug Monitoring of Adalimumab in Patients With Crohn's DiseaseKonstantinos Papamichael, Marla C Dubinsky, Adam S Cheifetz
Gastroenterology|April 17, 2021
Challenges and Opportunities in IBD Clinical Trial DesignMarla C Dubinsky, Rory Collins, Maria T Abreu, et al.
JAMA|September 21, 2021
Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction in Patients With Chronic Immune-Mediated Inflammatory DiseasesKonstantinos Papamichael, Marla C Dubinsky, Adam S Cheifetz
Gastrointestinal Endoscopy Clinics of North America|September 17, 2016
The First Endoscopy in Suspected Inflammatory Bowel DiseaseRebecca A Fausel, Asher Kornbluth, Marla C Dubinsky
Journal of Crohn'S & Colitis|September 7, 2020
Therapeutic Drug Monitoring of Anti-tumour Necrosis Factor Agents in Inflammatory Bowel Diseases: The Jury Is Still OutManasi Agrawal, Marla C Dubinsky, Jean-Frederic Colombel
Pageof 29